The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA

British Journal of Haematology

Volumn 102, Issue 5, 1998, Pages 1344-1353

  Keating, Susan ^a,j   De Witte, Theo ^b   Suciu, Stefan ^a   Willemze, Roel ^c   Hayat, Marcel ^d   Labar, Bokis ^e   Resegotti, Luigi ^f   Ferrini, Pierluigi Rossi ^g   Caronia, Francesco ^h   Dardenne, Murielle ^a   Solbu, Gabriel ^a   Petti, Maria Concetta ^h   Vegna, Maria Luce ^h   Mandelli, Franco ^h   Zittoun, Robert A ⁱ  

^a EORTC DATA CENTER   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e KBC Zagreb   (Croatia)

^f MAGGIORE HOSPITAL   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ HÔTEL DIEU   (France)

^j NONE   (Belgium)

more..

Author keywords

Acute myelogenous leukaemia; Allogeneic bone marrow transplantation; Autologous bone marrow transplantation; Donor availability; Intensive consolidation chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 7344264070     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1998.896hm3674.x     Document Type: Article

References (26)

1. Amadori, S., Arcese, W., Isacchi, G., Meloni, G., Petti, M.C., Monarca, B., Testi, A.M. & Mandelli, F. (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. Journal of Clinical Oncology, 9, 1210-1214.
2. Anderson, J.R. & Propert, K.J. (1989) A compendium of statistical terms and procedures used in cancer clinical trials. Advances in Oncology, 5, 7-26.
3. Archimbaud, E., Thomas, X., Michallet, M., Jaubert, J., Troncy, J., Guyotat, D. & Fière, D. (1994) Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology, 12, 262-267.
4. Büchner, T., Urbanitz, D., Hiddemann, W., Rühl, H., Ludwig, W.D., Fischer, J., Aul, H.C., Vaupel, H.A., Kuse, R.,Zeile, G., Nowrousian, M.R., König, H.J., Walter, M., Wendt, F.C., Sodomann, H., Hossfeld, D.K., von Paleske, A., Löffler, H., Gassmann, W., Hellriegel, K.P., Fülle, H.H., Lunscken, Ch, Emmerich, B., Pralle, H., Pees, W., Pfreundschuh, M., Bartels, H., Koeppen, K.M., Schwerdtfeger, R., Donhuijsen-Ant, R., Mainzer, K., Bonfert, B., Köppler, H., Zurborn, K.H., Ranft, K., Thiel, E. & Heinecke, A. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. Journal of Clinical Oncology, 3, 1583-1589.
5. Burnett, A.K., Goldstone, A.H., Wheatley, K., Rees, J.K., Stevens, R. & Hann, I. (1998) The role of BMT in AML in relation to prognostic characteristics. Acute Leukemias VII; Experimental Approaches and Novel Therapies, pp. 1093-1096.
6. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R., Hann, I., Rees, J.K., & Gray, R.G. for the MRC Leukaemia Working Parties (1994) Allogeneic IiMT in AML 10: Is having a matched donor an advantage? British Journal of Haematology, 78, (Suppl. 1), abst. 109.
7. Buyse, M.E., Staquet, M.J. & Sylvester, R.J. (1992) Cancer Clinical Trials: Methods and Practice. Oxford Medical Publications.
8. Cassileth, P.A., Harrington, D.P., Hines, J.D., Oken, M.N., Mazza, J.J., McGlave, P., Bennett, J.M. & O'Connell, M.J. (1988) Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. Journal of Clinical Oncology, 6, 583-587.
9. Champlin, R. & Gale, R.P. (1987) Acute myelogenous leukemia: recent advances in therapy. Blood, 69, 1551-1562.
10. Delmer, A., Marie, J.P., Thevenin, D., Suberville, A.M. & Zittoun, R. (1993) Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity. Leukemia and Lymphoma, 10, 67-71.
11. Gale, R.P. & Champlin, R.E. (1984) How does bone marrow transplantation cure leukemia? Lancet, ii. 28-30.
12. Gardner, M.J. & Altman, D.G. (1989) Statistics with confidence, confidence intervals and statistical guidelines. British Medical Journal, i. 64-70.
13. Gorin, N.C., Labopin, M., Meloni, G., Korbling, M., Carella, A., Herve, P., Burnett, A., Rizzoli, V., Allessandrino, E.P., Bjorkstrand, B., Ferrant, A., Löwenberg, P., Coser, R. Simonsson, B., Helbig, W., Brunet-Mauri, S., Verdonck, L.F., Iriondo, A., Polli, E., Colombat, P., Franklin, I.M., Souillet, G. & Willemze, R. for the European Cooperative Group for Bone and Marrow Transplantation (EBMT) (1991) Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: Further evidence of the role of marrow purging by mafosfamide. Leukemia, 5, 896-904.
14. Gray, R. & Wheatley, K. (1991) How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplantation, 7, (Suppl. 3), 9-12.
15. Kaplan, E.L & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
16. Keating, S., Suciu, S., de Witte, T., Mandelli, F., Willemze, R., Resegotti, L., Broccia, G., Thaler, J., Labar, B., Damasio, E., Bizzi, B., Rotoli, B., Vekhoff, A., Muus, P., Petti, M.C., Dardenne, M., Solbu, G., Vegna, M.L. & Zittoun, R.A. (1996) Prognostic factors of patients with acute leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A Trial. Bone Marrow Transplantation, 17, 993-1001.
17. Ljungman, P., de Witte, T., Verdonck, L., Gahrton, G., Freycon, F., Gravett, P., McCann, S., Morgenstern, H.G., Nikoskelainen, J., Powles, R., Proctor, S.J., Volin, L., Zwaan, F. & Grathwohl, A. (1993) Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. British Journal of Haematology, 84, 61-66.
18. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E., III (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903.
19. McMillan, A.K., Goldstone, A.H., Linch, D.C., Gribben, J.G., Patterson, K.G., Richards, J.D.M., Franklin, I., Boughton, B.J., Milligan, D.W., Leyland, M., Hutchinson, R.M. & Newland, A.C. (1990) High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood, 76, 480-488.
20. Reiffers, J., Gaspard, M.H., Maraninchi, D., Michallet, M., Marit, G., Stoppa, A.M., Corront, B., David, B., Gastaut, J.A., Scotto, J.J., Broustet, A., Carcassone, Y. & Hollard, U. (1989) Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. British Journal of Haematology, 72, 57-63.
21. Schattenberg, A., de Witte, T., Preijers, F., Raemaekers, J., Muus, R. Van der Lely, N., Boezeman, J., Wessels, J., van Dijk, B., Hoogenhout, J. & Haanen, C. (1990) Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood, 75, 1356-1363.
22. Suciu, S. (1991) The value of BMT in AML patients in first remission, a statistician's view-point. Annals of Hematology, 62, 41-44.
23. Zittoun, R., Jehn, U., Fière, D., Haanen, C., Löwenberg, B., Willemze, R., Abels, J., Bury, J., Peetermans, M., Hayat, M., Suciu, S., Solbu, G. & Stryckmans, P. (1989) Alternating repeated postremission treatment in adult acute myelogneous leukemia: a randomized phase III study (AML 6) of the EORTC Leukemia Cooperative Group. Blood, 73, 896-906.
24. Zittoun, R., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, R. Hayat, M., Stryckmans, P., Rotoli, B., Leoni, R. Peetermans, M.E., Dardenne, M., Vegna, M.L., Petti, M.C., Solbu, G. & Suciu, S. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine, 332, 217-225.
25. Zittoun, R., Suciu, S., Mandelli, R. de Witte, T., Thaler, J., Stryckmans, P., Hayat, M., Peetermans, M., Cadiou, M., Solbu, G., Petti, M.C. & Willemze, R. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology, 14, 2150-2159.
26. Zwaan, F.E., Hermans, J., Barrett, A.J. & Speck, B. (1984) Bone marrow transplantation for acute nonlymphoblastic leukaemia: a survey of the European Group for Bone Marrow Transplantation (EGBMT). British Journal of Haematology, 56, 645-653.